絞り込み

17713

広告

伊方原発3号機 定期検査 約半年ぶりに再開 トラブル相次ぎ中断 (NHK)

トラブルが相次いだことをうけて中断していた、愛媛県伊方町にある伊方原発3号機の定期検査について、四国電力は5日、およそ半年ぶりに再開しました。 伊方原発3号機は...

  1. 形成まもない銀河を現在の宇宙の中で発見 ...
  2. [医学] 間もなく増えるであろう小児の急...
  3. 台所のみ、売り上げ月500万円 レストラ...
  4. 埼玉県もTikTok利用停止 知事「情報...

ニュース一覧

Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies.

著者 Eggermont AM , Maio M , Robert C
Semin Oncol.2015 Jun ; 42(3):429-435.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (37view , 0users)

Full Text Sources

Medical

Research Materials

Immunotherapy has been revolutionalized by the concept of breaking tolerance. It represents a major paradigm shift that marks the beginning of a new era. The impact of the first checkpoint inhibitors, ie, anti-CTLA-4 (cytotoxic T lymphocyte antigen-4) and anti-PD-1/ anti-PD-L1 (programmed death-1 receptor and its ligand, PD-L1) is unprecedented. In only 5 years advanced melanoma has been transformed from an incurable disease into a curable disease, and we are only at the beginning of discovering its transversal impact throughout solid tumor oncology. In advanced melanoma response rates are about 12% for anti-CTLA-4 and about 40% for anti-PD-1, and are remarkably durable, hence their impact on survival. In melanoma anti-CTLA-4 (ipilimumab) was approved in 2011 and anti-PD-1 (pembrolimumab) in 2014. Another anti-PD-1 antibody (nivolumab) has been recently approved based on phase III trial results in metastatic melanoma without BRAF mutation. Ipilimumab already has been evaluated in the adjuvant setting (European Organization for Research and Treatment of Cancer [EORTC] 18071) and shown to significantly improve recurrence-free survival in stage III patients at high risk of relapse. An adjuvant trial to evaluate pembrolizumab in this population (EORTC 1325) was started in early 2015.
PMID: 25965361 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード